CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 49 enrolled
Drug / intervention
Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI +1 moredrug
Likely dose
Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDIfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01566149
NCT01566149Phase 3Completed
CompareCT.gov

An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects With Persistent Asthma (Protocol No. 206-00 [P08212])

Organon and Co·interventional·Posted Mar 29, 2012·Updated May 24, 2024

In Brief

A Phase 3 clinical trial evaluating Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI and Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI for Asthma. Completed, enrolled 49 participants.

Detailed Summary

The purpose of this study is to assess the safety, tolerability \& effectiveness of 2 strengths of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in the treatment of persistent asthma in adults \& adolescents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2012
Enrollment StartMar 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.3 years ago

Interventions

Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDIdrug

Two oral inhalations per dose

Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDIdrug

Two oral inhalations per dose